Premium
Bone microenvironment‐related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC‐3 prostate cancer cells
Author(s) -
Tenta Roxane,
Tiblalexi Despina,
Sotiriou Evangelia,
Lembessis Peter,
Manoussakis Menelaos,
Koutsilieris Michael
Publication year - 2003
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.10363
Subject(s) - zoledronic acid , doxorubicin , farnesyl pyrophosphate , prostate cancer , medicine , endocrinology , growth factor , pharmacology , transforming growth factor , cancer research , cancer , chemistry , chemotherapy , biochemistry , biosynthesis , receptor , enzyme
OBJECTIVES We analyzed the actions of zoledronic acid (10–250 μM) and doxorubicin (10–250 nM) on PC‐3 prostate cancer cells using both continuous (48–96 hr) and pulsatile exposures (15 min/day for up to three consecutive days). RESULTS The proliferation of PC‐3 cells was inhibited by either continuous or pulsatile exposures of zoledronic acid in a dose‐dependent manner. In contrast, pulsatile exposures of doxorubicin failed to inhibit the growth of PC‐3 cells. In addition, the inhibition of PC‐3 cells by zoledronic acid was partially neutralized by exogenous administration of geranylgeranyl pyrophosphate (GGPP), however, not by farnesyl pyrophosphate (FPP). Furthermore, exogenous administration of transforming growth factor beta 1 (TGF‐β1), interleukin 6 (IL‐6), basic fibroblast growth factor (bFGF), and more potently, insulin‐like growth factor 1 (IGF‐1) inhibited the doxorubicin‐induced apoptosis of PC‐3 cells. Under identical experimental conditions, these growth factors failed to alter the cytotoxicity of PC‐3 cells induced by zoledronic acid. CONCLUSIONS These data suggest that (i) repetitive and pulsatile (15 min/day) exposure to zoledronic acid inhibited the growth of PC‐3 cells, (ii) this anticancer action of zoledronic acid was partially mediated by the attenuation of GGPP production, and (iii) bone microenvironment‐related growth factors do not alter the anticancer actions of zoledronic acid on PC‐3 cells. © 2004 Wileey‐Liss, Inc.